Background. Although recent studies have focused on the use of metformin in treating ischemic stroke, there is little literature to support whether it can treat intracerebral hemorrhage (ICH). Therefore, this study is aimed at evaluating the possible effects of prestroke metformin (MET) on ICH patients with type 2 diabetes. Methods. From January 2010 to December 2019, all first-ever ICH patients with type 2 diabetes from our hospitals were included. All discharged patients would receive a one-time follow-up at 1 year after admission. Death, disability, and recurrence events were recorded. Results. We included 730 patients for analysis (the median age: 65 [IQR, 56-72] years and 57.7% was men). Of those patients, 281 (38.5%) had received MET before ICH (MET+), whereas 449 (61.5%) had not (MET−). MET (+) patients had a lower median baseline hematoma volume than did MET (-) patients (9.6 ml [IQR, 5.3-22.4 ml] vs. 14.7 ml [IQR, 7.9-28.6 ml]; ). The inhospital mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (6.4% vs 8.9%, respectively; absolute difference, −2.5% [95% CI, −3.9% to −0.7%]; OR, 0.70 [95% CI, 0.39 to 1.27]; ). The 1-year mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (14.1% vs 17.4%, respectively; absolute difference, −3.3% [95% CI, −5.1% to −1.8%]; OR, 0.73 [95% CI, 0.47 to 1.14]; ). The 1-year disability events were not significantly reduced in the MET (+) group compared with the MET (-) group (28.4% vs 34.1%, respectively; absolute difference, −5.7% [95% CI, −8.2% to −3.3%]; OR, 0.77 [95% CI, 0.52 to 1.13]; ). Finally, the recurrence rates in those two groups were not significantly different (MET [+] vs. MET [-]: 6.4% vs. 5.9%; absolute difference, 0.5% [95% CI, 0.2% to 1.3%]; OR, 1.08 [95% CI, 0.51 to 2.28]; ). Conclusions. Pre-ICH metformin use was not associated with inhospital mortality and 1-year prognosis in diabetic ICH patients.

中文翻译：

---

卒中前二甲双胍对 2 型糖尿病脑出血患者 1 年预后的影响

背景。尽管最近的研究集中在使用二甲双胍治疗缺血性中风，但很少有文献支持它是否可以治疗脑出血 (ICH)。因此，本研究旨在评估卒中前二甲双胍 (MET) 对 ICH 合并 2 型糖尿病患者的可能影响。方法。2010 年 1 月至 2019 年 12 月，纳入了我院所有首例 ICH 2 型糖尿病患者。所有出院患者均在入院后 1 年接受一次随访。记录死亡、残疾和复发事件。结果. 我们纳入了 730 名患者进行分析（中位年龄：65 [IQR，56-72] 岁，57.7% 为男性）。在这些患者中，281 名（38.5%）在 ICH（MET+）之前接受了 MET，而 449 名（61.5%）没有（MET-）。MET (+) 患者的中位基线血肿体积低于 MET (-) 患者（9.6 ml [IQR, 5.3-22.4 ml] vs. 14.7 ml [IQR, 7.9-28.6 ml]；）。与 MET (-) 组相比，MET (+) 组的住院死亡率事件未显着降低（分别为 6.4% 和 8.9%；绝对差异，-2.5% [95% CI，-3.9% 至 -0.7% ]；或，0.70 [95% CI，0.39 至 1.27]；）。与 MET (-) 组相比，MET (+) 组的 1 年死亡率事件没有显着降低（分别为 14.1% 和 17.4%；绝对差异，-3.3% [95% CI，-5.1% 至 - 1.8%]；或，0.73 [95% CI，0.47 至 1.14]；）。与 MET (-) 组相比，MET (+) 组的 1 年残疾事件没有显着减少（分别为 28.4% 和 34.1%；绝对差异，-5.7% [95% CI，-8.2% 至 - 3.3%]；或，0.77 [95% CI，0.52 至 1.13]；）。最后，这两组的复发率没有显着差异（MET [+] vs. MET [-]：6.4% vs. 5.9%；绝对差异，0.5% [95% CI，0.2% 至 1.3%]；或, 1.08 [95% CI, 0.51 至 2.28];）。 结论。ICH 前使用二甲双胍与糖尿病 ICH 患者的住院死亡率和 1 年预后无关。